UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 197

Sortiert nach

After the pandemic: perspectives on the future trajectory of COVID-19

Nature (London), 2021-08, Vol.596 (7873), p.495-504

2021

Volltextzugriff (PDF)

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2014-02, Vol.383 (9916), p.515-523

2014

Volltextzugriff (PDF)

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.736-743.e1

2014

Volltextzugriff (PDF)

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

The Lancet infectious diseases, 2015-06, Vol.15 (6), p.645-653

2015

Volltextzugriff (PDF)

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

The Lancet infectious diseases, 2015-09, Vol.15 (9), p.1049-1054

2015

Volltextzugriff (PDF)

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study

The Lancet infectious diseases, 2016-04, Vol.16 (4), p.459-464

2016

Volltextzugriff (PDF)

Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome

Gastroenterology (New York, N.Y. 1943), 2015-03, Vol.148 (3), p.616-625

2015

Volltextzugriff (PDF)

Simplified RNA secondary structure mapping by automation of SHAPE data analysis

Nucleic acids research, 2011-12, Vol.39 (22), p.e151

2011

Volltextzugriff (PDF)

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The New England journal of medicine, 2021-11, Vol.385 (21), p.1941-1950

2021

Volltextzugriff (PDF)

Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation

Blood advances, 2020-02, Vol.4 (4), p.617-628

2020

Volltextzugriff (PDF)

The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy

PloS one, 2009-08, Vol.4 (8), p.e6579-e6579

2009

Volltextzugriff (PDF)

Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2012-10, Vol.56 (10), p.5289-5295

2012

Volltextzugriff (PDF)

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

Gastroenterology (New York, N.Y. 1943), 2015-11, Vol.149 (6), p.1454-1461.e1

2015

Volltextzugriff (PDF)

Structural Map of a MicroRNA-122:Hepatitis C Virus Complex

Journal of Virology, 2012-01, Vol.86 (2), p.1250-1254

2012

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Gastroenterology (New York, N.Y. 1943), 2015-09, Vol.149 (3), p.649-659

2015

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

The New England journal of medicine, 2014-04, Vol.370 (16), p.1483-1493

2014

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

The New England journal of medicine, 2014-05, Vol.370 (20), p.1879-1888

2014

Volltextzugriff (PDF)

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Hepatology (Baltimore, Md.), 2016-10, Vol.64 (4), p.1049-1056

2016

Volltextzugriff (PDF)

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Gastroenterology (New York, N.Y. 1943), 2016-09, Vol.151 (3), p.501-512.e1

2016

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

The New England journal of medicine, 2015-08, Vol.373 (8), p.705-713

2015

Volltextzugriff (PDF)

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

JAMA : the journal of the American Medical Association, 2015-03, Vol.313 (12), p.1232

2015

Volltextzugriff (PDF)

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Hepatology (Baltimore, Md.), 2015-06, Vol.61 (6), p.1793-1797

2015

Volltextzugriff (PDF)

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

The Lancet infectious diseases, 2015-04, Vol.15 (4), p.397-404

2015

Volltextzugriff (PDF)

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

Journal of hepatology, 2023-10, Vol.79 (4), p.924-932

2023

Volltextzugriff (PDF)

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Englisch
(197)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(134)
Humans
(108)
Female
(55)
Male
(54)
Middle Aged
(44)
Aged
(34)
Cardiovascular System & Cardiology
(32)
Adult
(30)
Cardiac & Cardiovascular Systems
(30)
Hepacivirus - Genetics
(30)
Heart Failure
(29)
Infectious Diseases
(28)
Treatment Outcome
(27)
Genotype
(26)
Hepatitis C, Chronic - Drug Therapy
(26)
Acute Disease
(24)
Hepatitis C Virus
(24)
Uridine Monophosphate - Analogs & Derivatives
(23)
Antiviral Agents - Therapeutic Use
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

After the pandemic: perspectives on the future trajectory of COVID-19

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study

Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome

Simplified RNA secondary structure mapping by automation of SHAPE data analysis

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation

The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy

Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

Structural Map of a MicroRNA-122:Hepatitis C Virus Complex

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

Suchergebnisse filtern